News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Aleix Prat

Articles by Aleix Prat

118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS)

ByFabrice Andre,Peter A. Fasching,Aleix Prat,Patrick Neven, MD, PhD,Yen-Shen Lu,Aditya Bardia, MD, MPH, FASCO,Giuseppe Curigliano,Virginia Kaklamani, MD, DSc,Pedram Razavi,Yoon Sim Yap,Fei Su,Estelle Roux,Kristyn Pantoja,Jiwen Wu,Agnes Lteif,Dejan Juric

May 12th 2026

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

ByMario Campone,Louise Emmett,Dejan Juric,Debasish Tripathy,Sonia Pernas,Monica Zuradelli,Kevin Perraud,Aleix Prat

June 21st 2025

12 TIP HARMONIA SOLTI-2101/ AFT-58: A Head-to-Head Phase III Study Comparing Ribociclib (RIB) and Palbociclib (PAL) in Patients (pts) With Hormone Receptor– Positive/HER2-Negative/HER2- Enriched (HR+/HER2−/HER2-E) Advanced Breast Cancer (ABC)

ByLisa A. Carey, MD,Tomas Pascual,Daniel Stover,Astrid Thuerigen,Charles Perou,Eva Ciruelos,Ana Casas,Patty Spears,Estelle Roux,Faye Su,Hullin Hu,Yen-Shen Lu,Sara M. Tolaney, MD, MPH,Ann H. Partridge, MD, MPH,Guillermo Villacampa,Juan Manuel Ferrero-Cafiero,Aleix Prat

April 28th 2023

Latest Updated Articles

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC
June 21st 2025

Trending on CancerNetwork

FDA Approves Afami-cel in Metastatic Synovial Sarcoma

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC

How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?

Exploring the Future of Bladder-Sparing Regimens in the MIBC Landscape